Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
15 hedge funds and large institutions have $99.4K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 15 → 15 (0)
65% less capital invested
Capital invested by funds: $282K → $99.4K (-$182K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$22.9K |
| 2 |
CS
Clear Street
New York
|
+$149 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$46 |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$3.65K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$140 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAMP
1
Polar Asset Management Partners
Toronto,
Ontario, Canada
| $30.2K | – | – | – |
|
|
HCM
2
Highbridge Capital Management
New York
| $20.7K | – | – | – |
|
|
DCM
3
Driehaus Capital Management
Chicago,
Illinois
| $9.3K | +$22.9K | +750,000 | New |
|
|
FC
4
Finepoint Capital
Boston,
Massachusetts
| $8.58K | – | – | – |
|
|
6CM
5
683 Capital Management
New York
| $7.86K | – | – | – |
|
|
AC
6
Aristeia Capital
Greenwich,
Connecticut
| $6.9K | – | – | – |
|
7
Nomura Holdings
Tokyo,
Japan
| $6.08K | – | – | – |
|
|
SCM
8
Shaolin Capital Management
Miami,
Florida
| $4.33K | -$3.65K | -119,453 | -27% |
|
|
CAC
9
Cowen and Company
New York
| $2.25K | – | – | – |
|
|
EAM
10
Exos Asset Management
New York
| $1.38K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| $926 | +$6 | +200 | +0.3% |
|
12
Walleye Capital
New York
| $478 | – | – | – |
|
13
Walleye Trading
New York
| $263 | – | – | – |
|
|
CS
14
Clear Street
New York
| $87 | +$149 | +4,871 | +279% |
|
|
15
UBS Group
Zurich,
Switzerland
| $70 | +$46 | +1,497 | +38% |
|
|
FTUS
16
Flow Traders U.S.
New York
| – | -$140 | -4,586 | -29% |
|
CLDI.WS Hedge Fund Activity: Q3 2024 in Review
15 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q3 2024, worth a combined $99.4K — down 65% from $282K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CLDI.WS positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $22.9K. The largest seller was Shaolin Capital Management, cutting an estimated $3.65K.
- 15 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $99.4K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q3 2024, down 65% quarter-over-quarter.
- 1 fund opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q3 2024 was Driehaus Capital Management, an estimated $22.9K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q3 2024 was Shaolin Capital Management, an estimated $3.65K sold.
Based on aggregated 13F filings for Q3 2024.